This Trend Just Led Us to 174% Profits – And We Can Show You the Next Winner Today

Inside: A consumer trend to rival AI with proven triple-digit profit potential... [Derby City Daily logo] [Derby City Daily logo] This Trend Just Led Us to 174% Profits – And We Can Show You the Next Winner Today By Andy Swan It's hard to imagine an investing trend rivaling artificial intelligence (AI) here in 2023. So instead, let me show you one – because it allowed us to cash in on 174% gains this week... And the profits look poised to continue. This trend stems from the basic human tendency to find the easiest way out of a problem. Obesity is a big problem – affecting 42% of adults in America, according to the National Institutes of Health (NIH). And a “magic pill” is a whole lot more alluring than diet and exercise. So when folks found out type 2 diabetes treatments could help them shed weight in record time, social media was quick to catch on. Our proprietary system detected the skyrocketing interest as consumer mentions of taking a weight-loss drug zoomed 464% year-over-year, rivaling AI as one of LikeFolio’s top “investable” trends for 2023: These “magic pills” for weight loss go by a few different names: Semaglutide, Wegovy, Ozempic, Mounjaro... and they’re actually injections (though pill versions are in the works, [stimulating consumer interest even further](. 💊 Wegovy and Ozempic are brand names for the same generic GLP-1 drug, semaglutide. The difference: Wegovy is specifically approved as a weight-loss treatment while Ozempic is approved for type 2 diabetes. Both are sold by Novo Nordisk (NVO). Mounjaro (tirzepatide) is Eli Lilly’s (LLY) version, developed as a GLP-1 and GIP agonist for type 2 diabetes. Mounjaro is currently being reviewed by the FDA for weight loss. But the fact is that each of these drugs has proven to be remarkably effective in treating obesity... even if they’re not approved for that use (yet). And demand has exploded over the past year. Just take a look at the surge in social media buzz LikeFolio is recording for these drugs on a year-over-year basis: ✓ Semaglutide: +1,047% ✓ Wegovy: +1,345% ✓ Ozempic: +2,826% ✓ Mounjaro: +12,060% That’s translated into surging sales in 2023: For the second quarter, revenue from Novo’s GLP-1 diabetes segment grew 50%, while obesity care soared 157%. Wegovy sales alone accounted for $1.1 billion, its highest quarter on record. Influential celebrities from NBA great Charles Barkley to Tesla (TSLA) CEO Elon Musk touting their success stories have only added fuel to the fire. WW International (WW), better known as WeightWatchers, wanted a piece of that pie. So earlier this year, WW acquired telehealth provider Sequence – giving it the ability to connect its users via medical doctors to those trendy weight-loss drugs. The deal caused WW shares to jump 80% in 24 hours – from a closing price of $3.87 on March 6, the day of the announcement, to a closing price of $6.93 on March 7. We were early to the opportunity, recommending our paid-up [LikeFolio Investor]( subscribers buy WW shares back in December when our social media machine tipped us off that the company was gaining momentum with consumers. Under new leadership, we saw WW outperforming other weight management services and home fitness companies in demand while maintaining high levels of Consumer Happiness. That forward-looking call paid off massively for [LikeFolio Investor]( subscribers this week when we alerted them it was time to cash out. The result: a 174.73% return. If you missed out on those profits, don’t worry. We’re not resting on our laurels. We’re looking toward that next big play. And we already found our next weight-loss winner. [Check out this next company entering the weight-loss drug arena that has us even more excited than WW...]( [Click here to continue reading]( [Andy Swan's signature] [Andy Swan's signature] Andy Swan Senior Analyst, Derby City Insights © 2023 TradeSmith, LLC t/a Derby City Insights. All Rights Reserved. 1125 N. Charles Street, Baltimore, MD 21201 To unsubscribe or change your email preferences, please [click here](. [Terms of Use]( | [Privacy Policy](